argenx SE (NASDAQ:ARGX - Free Report) - Research analysts at Leerink Partnrs lowered their Q2 2025 EPS estimates for shares of argenx in a report released on Friday, May 9th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings per share of $2.19 for the quarter, down from their previous estimate of $2.40. The consensus estimate for argenx's current full-year earnings is $3.13 per share. Leerink Partnrs also issued estimates for argenx's Q3 2025 earnings at $2.60 EPS and Q4 2025 earnings at $2.93 EPS.
argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.32 by $0.26. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million.
Several other research firms have also weighed in on ARGX. Sanford C. Bernstein raised shares of argenx from a "market perform" rating to an "outperform" rating in a research note on Monday, March 17th. Guggenheim dropped their target price on shares of argenx from $1,100.00 to $1,065.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Oppenheimer raised their target price on shares of argenx from $704.00 to $708.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Robert W. Baird upgraded shares of argenx from a "neutral" rating to an "outperform" rating and set a $680.00 target price on the stock in a report on Tuesday. Finally, JMP Securities set a $699.00 target price on shares of argenx in a report on Wednesday. One investment analyst has rated the stock with a hold rating, twenty have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, argenx has a consensus rating of "Buy" and an average price target of $698.11.
Check Out Our Latest Stock Report on argenx
argenx Stock Down 0.2%
argenx stock traded down $1.40 during midday trading on Monday, hitting $560.35. 132,269 shares of the stock were exchanged, compared to its average volume of 322,284. The company has a fifty day simple moving average of $591.92 and a two-hundred day simple moving average of $612.84. argenx has a 52 week low of $356.38 and a 52 week high of $678.21. The stock has a market capitalization of $34.22 billion, a PE ratio of -635.80 and a beta of 0.57.
Hedge Funds Weigh In On argenx
Institutional investors have recently added to or reduced their stakes in the company. GeoWealth Management LLC increased its holdings in argenx by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after buying an additional 18 shares during the last quarter. Whipplewood Advisors LLC bought a new stake in shares of argenx in the fourth quarter valued at about $37,000. Global Retirement Partners LLC boosted its position in shares of argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after acquiring an additional 48 shares during the period. FIL Ltd bought a new stake in shares of argenx in the fourth quarter valued at about $38,000. Finally, Rakuten Securities Inc. lifted its position in argenx by 56.4% during the first quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock worth $36,000 after purchasing an additional 22 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.
argenx Company Profile
(
Get Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Featured Articles
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
